Novo Nordisk AS (WBO:NNO2) Change In Payables And Accrued Expense: €0 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WBO:NNO2 Novo Nordisk AS WBO:NNO2
80 GF Score
Price €40.08
GF Value €94.89
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is Novo Nordisk AS Change In Payables And Accrued Expense?

Novo Nordisk AS WBO:NNO2 +0.79% 80 Change In Payables And Accrued Expense is €0 Mil as of Jun. 2026. GuruFocus rates WBO:NNO2 with a GF Score™ of 80/100 and a GF Value™ of €94.89 (Significantly Undervalued). The stock has 3 warning signs investors should review.

Novo Nordisk AS's Change In Payables And Accrued Expense for the quarter that ended in Jun. 2026 was €0 Mil. It means Novo Nordisk AS's Accounts Payable & Accrued Expense stayed the same from Mar. 2026 to Jun. 2026 .

Novo Nordisk AS's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2025 was €0 Mil. It means Novo Nordisk AS's Accounts Payable & Accrued Expense stayed the same from Dec. 2024 to Dec. 2025 .

Novo Nordisk AS Change In Payables And Accrued Expense Historical Data

* Premium members only.

The historical data trend for Novo Nordisk AS's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novo Nordisk AS Change In Payables And Accrued Expense Chart

Novo Nordisk AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Change In Payables And Accrued Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 421.99 692.25 1,017.92 -37.55 0.00

Novo Nordisk AS Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Change In Payables And Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
WBO:NNO2
80GF Score
Novo Nordisk AS WBO:NNO2
Change In Payables And Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Novo Nordisk AS Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Change In Payables And Accrued Expense of €0 Mil mean?
Novo Nordisk AS (WBO:NNO2) has a Change In Payables And Accrued Expense of €0 Mil as of Jun. 2026. Change In Payables And Accrued Expense is any increase or decrease between periods of the payables and accrued expense. View historical data on Novo Nordisk AS and its competitors.
Is Novo Nordisk AS's Change In Payables And Accrued Expense too high?
Novo Nordisk AS's current Change In Payables And Accrued Expense is €0 Mil. Overall, Novo Nordisk AS has a GF Score™ of 80/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Novo Nordisk AS's Change In Payables And Accrued Expense compare to LLY and JNJ?
Novo Nordisk AS's Change In Payables And Accrued Expense of €0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Payables And Accrued Expense for a Drug Manufacturers company?
A good Change In Payables And Accrued Expense depends on the Drug Manufacturers industry context. However, Change In Payables And Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Payables And Accrued Expense mean?
A high Change In Payables And Accrued Expense can signal that a stock is expensive relative to its fundamentals. Change In Payables And Accrued Expense is any increase or decrease between periods of the payables and accrued expense. View historical data on Novo Nordisk AS and its competitors. Novo Nordisk AS's current Change In Payables And Accrued Expense is €0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novo Nordisk AS stock overvalued right now?
Based on GuruFocus' analysis, Novo Nordisk AS (WBO:NNO2) is currently considered Significantly Undervalued. The stock's GF Value™ is €94.89, compared to a current price of €40.08 — trading 57.8% below its estimated fair value. The current Change In Payables And Accrued Expense is €0 Mil. Novo Nordisk AS's overall GF Score™ is 80/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Payables And Accrued Expense calculated?
Change In Payables And Accrued Expense is calculated from a company's financial statements. For Novo Nordisk AS (WBO:NNO2), the current Change In Payables And Accrued Expense is €0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Novo Nordisk AS (WBO:NNO2) Overvalued in 2026?

Based on GuruFocus' analysis, Novo Nordisk AS stock appears to be undervalued. The current stock price of €40.08 is trading 57.8% below its estimated GF Value™ of €94.89. GuruFocus considers Novo Nordisk AS to be Significantly Undervalued.

Key valuation signals for WBO:NNO2:

  • Change In Payables And Accrued Expense: €0 Mil
  • GF Value™: €94.89 vs. price of €40.08 (57.8% below fair value)
  • GF Score™: 80/100 with 3 warning signs

No single metric tells the full story. See the WBO:NNO2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Novo Nordisk AS Business Description

Address Novo Alle 1, Bagsvaerd, DNK, 2880
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
80GF Score

Get the complete analysis for WBO:NNO2

Change In Payables And Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€40.08
Price
€94.89
GF Value